Literature DB >> 15158372

Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.

Viviane M C Guimarães1, Antonio W Zuardi, Elaine Aparecida Del Bel, Francisco S Guimarães.   

Abstract

Preclinical and clinical studies suggest that cannabidiol (CBD), a major component of Cannabis sativa, could produce antipsychotic effects without causing extra-pyramidal side-effects. In the present paper we employed the detection of Fos protein to investigate neuronal activation in the dorsal striatum and nucleus accumbens of male Wistar rats after systemic administration of CBD (120 mg/kg), haloperidol (1 mg/kg) or clozapine (20 mg/kg). Only haloperidol was able to increase the number of Fos immunoreactive neurons (FIr) in the dorsal striatum (vehicle: 0.07 +/- 0.07/0.1 mm(2), haloperidol: 28.3 +/- 8.9/0.1 mm(2), p < 0.01). In contrast, both haloperidol and CBD significantly increased FIr in the nucleus accumbens (Vehicle: 0 +/- 0/0.1 mm(2), haloperidol: 7.2 +/- 2.7/0.1 mm(2), CBD: 4.0 +/- 1.9/0.1 mm(2), p < 0.05). Clozapine also produced a barely significant increase in FIr (3.0 +/- 1.7/0.1 mm(2), p = 0.062). These results show that CBD is able to induce FIr in a limbic- but not in a motor-related area.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158372     DOI: 10.1016/j.lfs.2004.01.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

Review 1.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.

Authors:  Daniel T Malone; Matthew N Hill; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.

Authors:  J F C Pedrazzi; A C Issy; F V Gomes; F S Guimarães; E A Del-Bel
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

3.  Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.

Authors:  S M Todd; J C Arnold
Journal:  Br J Pharmacol       Date:  2015-11-18       Impact factor: 8.739

4.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

Review 5.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 6.  Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Authors:  Alline Cristina Campos; Fabricio Araújo Moreira; Felipe Villela Gomes; Elaine Aparecida Del Bel; Francisco Silveira Guimarães
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

7.  Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System.

Authors:  Christopher Norris; Michael Loureiro; Cecilia Kramar; Jordan Zunder; Justine Renard; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2016-06-14       Impact factor: 7.853

8.  Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Authors:  Eva M Marco; María S García-Gutiérrez; Francisco-Javier Bermúdez-Silva; Fabricio A Moreira; Francisco Guimarães; Jorge Manzanares; María-Paz Viveros
Journal:  Front Behav Neurosci       Date:  2011-10-05       Impact factor: 3.558

9.  Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.

Authors:  Raquel Levin; Fernanda F Peres; Valéria Almeida; Mariana B Calzavara; Antonio W Zuardi; Jaime E C Hallak; José Alexandre S Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

10.  Potential effects of cannabidiol as a wake-promoting agent.

Authors:  Eric Murillo-Rodríguez; Andrea Sarro-Ramírez; Daniel Sánchez; Stephanie Mijangos-Moreno; Alma Tejeda-Padrón; Alwin Poot-Aké; Khalil Guzmán; Elda Pacheco-Pantoja; Oscar Arias-Carrión
Journal:  Curr Neuropharmacol       Date:  2014-05       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.